Can measuring DNA transcription infidelity enable a more personalised approach to treating cancer?

Can measuring DNA transcription infidelity enable a more personalised approach to treating cancer?

Bernard Bihain, CEO to Genclis SAS is interviewed on PharmaTV

Bernard Bihain, CEO to Genclis SAS, reveals how their diagnostic approach could help clinicians predict the severity of cancers, and devise more optimised treatment plans.

https://www.pharmatelevision.com/Video/1390-PTVNRBernardBihain.aspx

要查看或添加评论,请登录

Graham Combe的更多文章

社区洞察

其他会员也浏览了